All-share transaction: Recognify shareholders – including atai Life Sciences, Catalio Capital Management and Sudhoff Family Office – become shareholders of AmyriAD

全股份交易：Recognify的股东——包括atai Life Sciences、Catalio Capital Management和Sudhoff Family Office——成为AmyriAD的股东

RL-007 adds a differentiated clinical-stage cognition program in Cognitive Impairment Associated with Schizophrenia (CIAS) and Alzheimer's disease

RL-007 增加了针对精神分裂症相关认知障碍（CIAS）和阿尔茨海默病的差异化临床阶段认知研究项目

AMSTERDAM and SHERWOOD, Ore.

阿姆斯特丹和俄勒冈州舍伍德

,

，

Oct. 7, 2026

2026年10月7日

/PRNewswire/ -- AmyriAD Therapeutics B.V. ('AmyriAD'), a clinical-stage biopharmaceutical company focused on cognition in central nervous system disorders, today announced the acquisition of Recognify Life Sciences, Inc. ('Recognify') and its lead clinical-stage program, RL-007 (inidascamine). The acquisition expands AmyriAD's cognition pipeline while preserving Ismidenon (AD-101) as the company's lead Alzheimer's disease program..

/美通社/ -- 专注于中枢神经系统疾病认知障碍的临床阶段生物制药公司AmyriAD Therapeutics B.V.（“AmyriAD”）今日宣布收购Recognify Life Sciences, Inc.（“Recognify”）及其领先的临床阶段项目RL-007（inidascamine）。此次收购扩大了AmyriAD在认知领域的产品管线，同时保留Ismidenon（AD-101）作为公司主要的阿尔茨海默病项目。

RL-007 is an orally administered, first-in-class pro-cognitive compound that modulates cholinergic, glutamatergic and GABA-B receptor activity, designed to restore the balance of excitatory and inhibitory signaling that underlies cognitive dysfunction across multiple CNS disorders. The compound has been studied in 500 subjects to date and has demonstrated a consistent safety and tolerability profile, with no evidence of sedation, weight gain or extrapyramidal symptoms in its most recent Phase 2b study..

RL-007 是一种口服给药的首创类促认知化合物，可调节胆碱能、谷氨酸能和 GABA-B 受体活性，旨在恢复多种中枢神经系统疾病中认知功能障碍所基础的兴奋性与抑制性信号平衡。截至目前，该化合物已在 500 名受试者中进行研究，并展现出一致的安全性和耐受性特征；在其最近的 IIb 期临床试验中，未发现镇静、体重增加或锥体外系症状的证据。

Strategic Rationale

战略理由

The acquisition strengthens AmyriAD's clinical-stage cognition pipeline while preserving Ismidenon as the company's lead Alzheimer's disease program.

此次收购增强了AmyriAD在临床阶段的认知障碍研发管线，同时保留Ismidenon作为公司领先的阿尔茨海默病项目。

RL-007 adds a differentiated pro-cognitive mechanism with clinical-stage experience in Cognitive Impairment Associated with Schizophrenia (CIAS), giving AmyriAD greater depth within cognition while creating a second development path in a large, underserved CNS indication.

RL-007 增加了一种差异化的促认知机制，并具备在精神分裂症相关认知障碍（CIAS）领域的临床阶段经验，这不仅增强了 AmyriAD 在认知领域的深度，还为其在一个庞大且未满足需求的中枢神经系统适应症中开辟了第二条开发路径。

'RL-007 fits squarely into what AmyriAD was built to do,' said Ranga Krishnan, M.D., Chair of the Board of AmyriAD. 'We are a cognition company. Our lead asset, ismidenon, targets cognitive decline in Alzheimer's disease, and RL-007 adds clinical-stage depth to that same strategic focus through a differentiated mechanism and a second cognition indication that has already shown pro-cognitive signals in schizophrenia.

“RL-007 完全契合 AmyriAD 的创立使命，”AmyriAD 董事会主席 Ranga Krishnan 医学博士表示。“我们是一家专注于认知领域的公司。我们的核心资产 ismidenon 旨在靶向阿尔茨海默病相关的认知衰退，而 RL-007 则凭借其独特的作用机制以及在精神分裂症中已显示出促认知信号的第二个认知适应症，为这一战略重点增添了临床阶段的深度。”

The Phase 2b data taught us a great deal about dose, exposure and endpoint selection. We intend to apply those learnings to a reformulated product and a sharper clinical program in both CIAS and Alzheimer's disease. We are equally pleased to welcome atai, Catalio and Sudhoff as shareholders of AmyriAD – investors who know this asset well and share our conviction in it.'.

2b期数据让我们对剂量、暴露量和终点选择有了深入的了解。我们打算将这些经验应用于配方改良后的产品，并在CIAS和阿尔茨海默病领域开展更为精准的临床项目。我们同样高兴地欢迎atai、Catalio和Sudhoff成为AmyriAD的股东——这些投资者对本资产有着深刻的了解，并与我们一样对其充满信心。

'AmyriAD's singular focus on cognition and its experienced CNS team make it the right owner to take inidascamine forward. As shareholders, we look forward to participating in the program's next chapter,' said Matthew P. Pando, Ph.D., President & CEO of Recognify Life Sciences.

“AmyriAD 对认知领域的专注以及其中枢神经系统经验丰富的团队，使其成为推动 inidascamine 向前发展的合适所有者。作为股东，我们期待参与该项目的下一阶段。”Recognify Life Sciences 总裁兼首席执行官 Matthew P. Pando 博士表示。

Development Plan

发展计划

AmyriAD intends to:

AmyriAD 旨在：

Optimize RL-007 formulation and exposure

优化 RL-007 的配方与暴露条件

: A pharmacokinetic study initiated by Recognify is ongoing and will be completed by AmyriAD, with results expected in H1 2027.

由 Recognify 发起的一项药代动力学研究正在进行中，将由 AmyriAD 完成，预计结果将于 2027 年上半年公布。

Advance RL-007 in CIAS

在CIAS中推进RL-007

: CIAS represents a substantial unmet need with no approved therapies specifically targeting cognitive impairment. Cognitive impairment is estimated to affect more than 80% of the approximately 24 million people living with schizophrenia worldwide. While RL-007 did not meet statistical significance on the MCCB neurocognitive composite at week 6 in the Phase 2b study (n=242), numerical improvements were observed across several cognitive domains, including Symbol Coding, Speed of Processing and Verbal Learning, along with directionally positive effects on functional capacity as measured by VRFCAT.

CIAS 代表了巨大的未满足医疗需求，目前尚无专门针对认知障碍的获批疗法。据估计，在全球约 2400 万精神分裂症患者中，超过 80% 受到认知障碍的影响。尽管在二期 b 阶段研究（n=242）的第 6 周，RL-007 在 MCCB 神经认知综合评分上未达到统计学显著性，但在多个认知领域（包括符号编码、处理速度和言语学习）观察到了数值上的改善，并且通过 VRFCAT 测量的功能能力也显示出方向性的积极效应。

The reformulated product and refined trial design will build on these findings by focusing on the domains where the strongest signals were observed..

重新配制的产品和优化的试验设计将基于这些发现，重点关注观察到最强信号的领域。

Initiate development in disorders with cognition impairment

在伴有认知障碍的疾病中启动开发

: Leveraging AmyriAD's existing clinical infrastructure, investigator network and regulatory experience from the ismidenon program, a Phase 2 study in mild-to-moderate Alzheimer's disease is planned for 2027/2028.

利用AmyriAD现有的临床基础设施、研究者网络以及从ismidenon项目中获得的监管经验，计划于2027/2028年开展一项针对轻度至中度阿尔茨海默病的II期临床研究。

Transaction Terms

交易条款

Under the terms of the agreement, AmyriAD acquired Recognify and the rights and assets associated with RL-007. The transaction included an equity-based consideration structure with additional consideration linked to future development milestones. AmyriAD will support the continued development of RL-007, including completion of the ongoing pharmacokinetic study, with transition support expected from members of the Recognify team..

根据协议条款，AmyriAD 收购了 Recognify 以及与 RL-007 相关的权利和资产。该交易包含基于股权的对价结构，并设有与未来开发里程碑挂钩的额外对价。AmyriAD 将支持 RL-007 的持续开发，包括完成正在进行的药代动力学研究，预计 Recognify 团队成员将提供过渡期支持。

About RL-007 (inidascamine)

关于RL-007（inidascamine）

RL-007 is an orally available small molecule that modulates cholinergic, glutamatergic and GABA-B receptor signaling to enhance cognitive function. Advanced clinically by Recognify Life Sciences, RL-007 has completed Phase 2a and Phase 2b studies in cognitive impairment associated with schizophrenia.

RL-007 是一种口服小分子药物，通过调节胆碱能、谷氨酸能和 GABA-B 受体信号传导来增强认知功能。由 Recognify Life Sciences 推进临床开发，RL-007 已完成针对精神分裂症相关认知障碍的 IIa 期和 IIb 期临床研究。

Across its clinical program, RL-007 has been well tolerated, with a safety profile that distinguishes it from many CNS agents..

在RL-007的整个临床项目中，该药物耐受性良好，其安全性特征使其区别于许多中枢神经系统药物。

About AmyriAD Therapeutics

关于 AmyriAD 治疗公司

AmyriAD Therapeutics B.V. is a clinical-stage biopharmaceutical company focused on restoring cognitive function in CNS disorders. The company's lead program, ismidenon, is a T-type calcium channel modulator being developed as a symptomatic treatment for cognitive impairment in Alzheimer's disease on top of standard of care, with a Phase 2b study planned to begin dosing in 2027.

AmyriAD Therapeutics B.V. 是一家处于临床阶段的生物制药公司，专注于恢复中枢神经系统（CNS）疾病患者的认知功能。公司的核心项目 ismidenon 是一种 T 型钙通道调节剂，旨在作为标准治疗之外的附加疗法，用于改善阿尔茨海默病相关的认知障碍症状；其 IIb 期临床试验计划于 2027 年开始给药。

AmyriAD is building a focused portfolio of clinical-stage cognition assets through disciplined, equity-based acquisitions. The company is headquartered in Amsterdam, the Netherlands, with U.S. operations through AmyriAD Pharma, Inc. in Sherwood, Oregon. For more information, visit .

AmyriAD 通过纪律严明的股权收购，构建专注于临床阶段认知领域资产的组合。公司总部位于荷兰阿姆斯特丹，并通过位于俄勒冈州舍伍德的 AmyriAD Pharma, Inc. 在美国开展业务。欲了解更多信息，请访问。

www.amyriadtherapeutics.com

www.amyriadtherapeutics.com

.

。

About Recognify Life Sciences

关于 Recognify Life Sciences

Recognify Life Sciences, Inc. is a clinical-stage biotechnology company founded to develop pro-cognitive treatments for patients with schizophrenia and other CNS disorders. Prior to the acquisition, Recognify was a portfolio company of atai Life Sciences, backed by Catalio Capital Management and Sudhoff Family Office.

Recognify Life Sciences, Inc. 是一家处于临床阶段的生物技术公司，成立旨在为精神分裂症及其他中枢神经系统（CNS）疾病患者开发促认知疗法。在被收购之前，Recognify 是 atai Life Sciences 旗下的一家投资组合公司，由 Catalio Capital Management 和 Sudhoff Family Office 提供资金支持。

Recognify is now a wholly owned subsidiary of AmyriAD Therapeutics..

Recognify 现在是 AmyriAD Therapeutics 的全资子公司。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements, including statements regarding the anticipated benefits of the acquisition, the planned reformulation of RL-007, the timing, design and outcome of future clinical studies in CIAS and Alzheimer's disease, and AmyriAD's development strategy and financing plans.

本新闻稿包含前瞻性陈述，包括关于收购预期收益、RL-007的重新配方计划、CIAS和阿尔茨海默病未来临床研究的时间安排、设计和结果，以及AmyriAD的发展战略和融资计划的陈述。

These statements are based on current expectations and are subject to risks and uncertainties, including the risk that clinical results will not replicate earlier findings, that regulatory authorities may require additional studies, that AmyriAD may not obtain sufficient funding to execute its plans, and other risks inherent in drug development.

这些陈述基于当前预期，并受各种风险和不确定性的影响，包括临床试验结果未能复现早期发现的风险、监管机构可能要求开展额外研究的风险、AmyriAD 可能无法获得足够资金以执行其计划的风险，以及药物开发过程中固有的其他风险。

AmyriAD undertakes no obligation to update forward-looking statements except as required by law. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities..

AmyriAD 除法律要求外，不承担更新前瞻性陈述的义务。本新闻稿不构成出售任何证券的要约，也不构成购买任何证券的要约邀请。

Contacts

联系人

Kim Bruin,

金·布鲁因，

[email protected]

[email protected]

(Investors)

（投资者）

Ankil Patel, 917-561-6464,

安基尔·帕特尔，917-561-6464，

[email protected]

[email protected]

(Media)

（媒体）

SOURCE AmyriAD Therapeutics

来源：AmyriAD Therapeutics

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示